Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route (Ascending) Package Effective Date Package Discontinuation Date Status
70860-0785-05 70860-0785 Palonosetron hydrochloride Palonosetron Hydrochloride 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Oct. 1, 2022 Feb. 28, 2025 In Use
83257-0001-11 83257-0001 Trastuzumab-dkst OGIVRI 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct. 1, 2023 In Use
83257-0003-01 83257-0003 Trastuzumab-dkst OGIVRI 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct. 1, 2023 In Use
00338-9581-02 00338-9581 Doxorubicin hydrochloride Doxorubicin hydrochloride, Liposomal 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Dec. 19, 2023 In Use
10702-0361-99 10702-0361 Carmustine Carmustine Chemotherapy Alkylating Agent Nitrosourea Intravenous March 1, 2024 In Use
25021-0248-51 25021-0248 Cyclophosphamide Cyclophosphamide 1.0 g/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Jan. 15, 2024 In Use
25021-0249-51 25021-0249 Cyclophosphamide Cyclophosphamide 2.0 g/100mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Jan. 15, 2024 In Use
25021-0255-05 25021-0255 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 1, 2024 In Use
25021-0255-17 25021-0255 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 1, 2024 In Use
25021-0255-50 25021-0255 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 1, 2024 In Use
39822-0250-01 39822-0250 Cyclophosphamide CYCLOPHOSPHAMIDE 500.0 mg/25mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Dec. 19, 2023 In Use
39822-0255-01 39822-0255 Cyclophosphamide CYCLOPHOSPHAMIDE 1.0 g/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Dec. 19, 2023 In Use
55150-0270-01 55150-0270 Cyclophosphamide Cyclophosphamide 500.0 mg/2.5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Aug. 25, 2021 In Use
55150-0270-99 55150-0270 Cyclophosphamide Cyclophosphamide 500.0 mg/2.5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 20, 2023 In Use
55150-0271-01 55150-0271 Cyclophosphamide Cyclophosphamide 1.0 g/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Aug. 25, 2021 In Use
55150-0271-99 55150-0271 Cyclophosphamide Cyclophosphamide 1.0 g/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 20, 2023 In Use
55150-0272-01 55150-0272 Cyclophosphamide Cyclophosphamide 2.0 g/10mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 20, 2023 In Use
68001-0608-24 68001-0608 Cisplatin CISPLATIN 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 1, 2024 In Use
68001-0609-33 68001-0609 Cisplatin CISPLATIN 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 1, 2024 In Use
68083-0233-06 68083-0233 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Jan. 3, 2024 In Use
68083-0388-01 68083-0388 Dexrazoxane for Injection Dexrazoxane 250.0 mg/25mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous Dec. 16, 2019 In Use
71288-0171-11 71288-0171 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 11, 2024 In Use
71288-0172-21 71288-0172 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 11, 2024 In Use
72205-0171-07 72205-0171 ARSENIC TRIOXIDE ARSENIC TRIOXIDE 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Feb. 6, 2024 In Use
72205-0172-07 72205-0172 ARSENIC TRIOXIDE ARSENIC TRIOXIDE 2.0 mg/2mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Feb. 6, 2024 In Use

Found 10,000 results in 4 millisecondsExport these results